Aggiornamento Clinico Scientifico Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment
a cura di Tania Pilli
Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS.
Background: Low doses of antithyroid drugs (ATD) for extended periods may be an alternative for Graves' disease (GD) patients who relapse after a course of ATD
LEGGI TUTTO
Aggiornamento Clinico Scientifico Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement
a cura di Andrea Lania
Sabine M. Staufenbiel, Cornelie D. Andela, Laura Manenschijn, Alberto M. Pereira, Elisabeth F. C. van Rossum, and Nienke R. Biermasz
J Clin Endocrinol Metab. 2015 Jun;100(6):2456-62
Intrinsic imperfections and lack of reliable biomarkers preclude optimal individual dosing of hydrocortisone replacement in adrenal insufficiency (AI). However, the clinical relevance of optimal dosing
LEGGI TUTTO
Aggiornamento Clinico Scientifico Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus. A Scientific Statement From the American Heart Association
a cura di Daniele Gianfrilli
Regensteiner J.G., Golden S., Huebschmann A. G., Barrett-Connor E., Chang A. Y., Chyun D., Fox C. S., Kim C., Mehta N., Reckelhoff J. F., Reusch J. E.B., Rexrode K. M., Summer A. E., Welty F. K., Wenger N. K. and Anton B.
Circulation. 2015 Dec 22;132(25):2424-47
The prevalence of diabetes mellitus (DM) is increasing at a rapid rate. In the United State in 2012, 29.1 million Americans, or 9.3% of the population, had DM. Currently, ~1 in 13 people living in the United States has DM, and 90% to 95% of these individuals have type 2 DM (T2DM).
LEGGI TUTTO
Aggiornamento Clinico Scientifico
Larouche V, Correa JA, Cassidy P, Beauregard C, Garfield N, Rivera J.
Pituitary. 2015 Dec 23.
Prolactin can affect autoimmune response and evidence suggests that hyperprolactinemia can primarily precipitate autoimmunity. We postulate that patients with prolactinomas are more prone to autoimmune disease (AID).
LEGGI TUTTO
Aggiornamento Clinico Scientifico
a cura di Giuseppe Bellastella
Emily J. Gianatti, Rudolf Hoermann, Que Lam, Philippe Dupuis, Jeffrey D. Zajac, and Mathis Grossmann
Clinical Endocrinology (2016) 84, 55–62
To assess the effect of testosterone treatment on cardiac biomarkers in men with type 2 diabetes (T2D). Design Randomized double-blind, parallel, placebo-controlled trial. Patients Men aged 35– 70 years with T2D and a total testosterone level
LEGGI TUTTO
Aggiornamento Clinico Scientifico
a curadi Marco Giorgio Baroni
Boussageon R, Gueyffier F, Cornu C.
BMJ. 2016 Jan 8;352:h6748.
Metformin is recommended as the first glucose lowering treatment for people with type 2 diabetes.1 The recommendation is based on the supposedly conclusive results of the UK Prospective Diabetes Study (UKPDS 34) published in 1998.
LEGGI TUTTO